Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perjeta Among Biosimilar Targets As Viatris Insists It Can ‘Do A Lot More’

Viatris Has Identified 13 New Biosimilar Targets For Development

Executive Summary

At Viatris’ inaugural investor day, management spoke at length about the company’s ambitions for biosimilars, underlining that the company currently had no plans to expand its manufacturing footprint at the present time.

You may also be interested in...



Viatris Expects First Interchangeable Biosimilar Designations For Insulins In July

Amid continued debate over biosimilar interchangeability in the US, Viatris has said it expects to pick up the first such approvals later this year with the company’s insulin glargine and insulin aspart biosimilar products.

Viatris And Biocon Line Up EU Bevacizumab

Viatris’ Mylan has received a positive opinion from the EMA’s CHMP for its bevacizumab biosimilar rival to Avastin under two different names. Meanwhile, Accord has received an endorsement for a generic version of Zytiga.

Viatris Share Price Plunges Amid Weak 2021 Financial Guidance

Viatris’ share price closed the day nearly 15% down after announcing weaker than anticipated revenue, adjusted EBITDA and cash flow guidance for 2021. The market reacted strongly to the company’s expectations and ambitions, with management continuing to stress the strength of the combined Mylan and Upjohn businesses.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150728

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel